BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37053008)

  • 1. Ubiquitin-proteasome system-mediated ubiquitination modification patterns and characterization of tumor microenvironment infiltration, stemness and cellular senescence in low-grade glioma.
    Gu J; Pang L; Yan D; Wang C; Song Y; Jin Z; Xu Z; Mao Y; Liu S; Chen S
    Aging (Albany NY); 2023 Apr; 15(8):2970-2998. PubMed ID: 37053008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of three heterogeneous subtypes and a risk model of low-grade gliomas based on cell senescence-related genes.
    Chen J; Wu L; Yang H; Zhang X; Xv S; Qian Q
    Front Immunol; 2022; 13():982033. PubMed ID: 36052073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma.
    Du J; Ji H; Ma S; Jin J; Mi S; Hou K; Dong J; Wang F; Zhang C; Li Y; Hu S
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33594424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Mitochondrial Ribosomal RNA Modification-Based Classification Contributes to Discriminate the Prognosis and Immunotherapy Response of Glioma Patients.
    Wang P; Li J; Wu M; Ye M; Huang K; Zhu X
    Front Immunol; 2021; 12():722479. PubMed ID: 34566979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
    Li Y; Feng Y; Luo F; Peng G; Li Y
    Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. m
    Zhang B; Wu Q; Li B; Wang D; Wang L; Zhou YL
    Mol Cancer; 2020 Mar; 19(1):53. PubMed ID: 32164750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of m6A Regulator-Mediated Methylation Modification and Tumor Microenvironment Infiltration in Glioblastoma Multiforme.
    Wang L; Cao H; Zhong Y; Ji P; Chen F
    Front Cell Dev Biol; 2022; 10():842835. PubMed ID: 35265626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.
    Guo Y; Bai Y; Wang L; Xu Z; Wang X; Wang W
    Medicine (Baltimore); 2022 Jul; 101(26):e29818. PubMed ID: 35777046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating m6A Regulators-Mediated Methylation Modification Models and Tumor Immune Microenvironment Characterization in Caucasian and Chinese Low-Grade Gliomas.
    Liu W; Li C; Wu Y; Xu W; Chen S; Zhang H; Huang H; Zhao S; Wang J
    Front Cell Dev Biol; 2021; 9():725764. PubMed ID: 34900988
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of APOBEC3C in modulating the tumor microenvironment and stemness properties of glioma: evidence from pancancer analysis.
    Zhang S; Guo Y; Hu Y; Gao X; Bai F; Ding Q; Hou K; Wang Z; Sun X; Zhao H; Qu Z; Xu Q
    Front Immunol; 2023; 14():1242972. PubMed ID: 37809064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. m6A Regulators Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization In Nasopharyngeal Carcinoma.
    Liu Z; He J; Han J; Yang J; Liao W; Chen N
    Front Immunol; 2021; 12():762243. PubMed ID: 35069534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. H4-methylation regulators mediated epitranscriptome patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
    Yu L; Ji T; Liao W; Xu Y; Fang Y; Zhu Q; Nie J; Yang D
    Clin Epigenetics; 2023 Mar; 15(1):43. PubMed ID: 36932439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular subtypes of osteosarcoma classified by cancer stem cell related genes define immunological cell infiltration and patient survival.
    Guo L; Yan T; Guo W; Niu J; Wang W; Ren T; Huang Y; Xu J; Wang B
    Front Immunol; 2022; 13():986785. PubMed ID: 36059448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of ubiquitin pathway-mediated regulation of immune checkpoints in cancer immunotherapy.
    Zhou X; Fu C; Chen X
    Cancer; 2023 Jun; 129(11):1649-1661. PubMed ID: 36857206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment.
    Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z
    Front Immunol; 2021; 12():691811. PubMed ID: 34489938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
    Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
    Front Immunol; 2022; 13():933973. PubMed ID: 36045691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
    Huang X; Qiu Z; Li L; Chen B; Huang P
    Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of RNA-modification "writer" genes with prognosis and response to immunotherapy in patients with low-grade glioma.
    Zhang L; Qu C; Shi C; Wu F; Tang Y; Li Y; Li J; Feng H; Zhong S; Yang J; Zeng X; Peng X
    PLoS One; 2023; 18(1):e0279119. PubMed ID: 36649311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy.
    Zhao B; Xiang Z; Wu B; Zhang X; Feng N; Wei Y; Zhang W
    Curr Pharm Des; 2023; 29(1):60-78. PubMed ID: 36503445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.